Highlights Newsletter 3
This newsletter presents you the following key sessions:
2. Navigating secondary acute myeloid leukaemia in 2023
4. Belantamab mafodotin versus pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma
This newsletter presents you the following key sessions:
2. Navigating secondary acute myeloid leukaemia in 2023
4. Belantamab mafodotin versus pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma
Medical writer
Medical writer
Medical writer